These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 24622714)
1. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714 [TBL] [Abstract][Full Text] [Related]
2. Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database. Soranna D; Bosetti C; Casula M; Tragni E; Catapano AL; Vecchia CL; Merlino L; Corrao G Diabetes Res Clin Pract; 2015 May; 108(2):243-9. PubMed ID: 25748827 [TBL] [Abstract][Full Text] [Related]
3. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan. Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712 [TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapy and risk of cholangiocarcinoma: a nested case-control study in a population of subjects with type 2 diabetes. Giorda CB; Picariello R; Tartaglino B; Nada E; Costa G; Gnavi R Acta Diabetol; 2020 Apr; 57(4):401-408. PubMed ID: 31691043 [TBL] [Abstract][Full Text] [Related]
6. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis? Olansky L Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512 [No Abstract] [Full Text] [Related]
7. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260 [TBL] [Abstract][Full Text] [Related]
8. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423 [TBL] [Abstract][Full Text] [Related]
9. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930 [TBL] [Abstract][Full Text] [Related]
10. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555 [TBL] [Abstract][Full Text] [Related]
11. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)]. Jermendy G Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851 [TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Roshanov PS; Dennis BB Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128 [TBL] [Abstract][Full Text] [Related]
13. Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: A population-based case-control study in Taiwan. Liao KF; Lin CL; Lai SW; Chen WC Eur J Intern Med; 2016 Jan; 27():76-9. PubMed ID: 26433909 [TBL] [Abstract][Full Text] [Related]
14. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555 [TBL] [Abstract][Full Text] [Related]
15. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. Wilhite K; Reid JM; Lane M Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Giorda CB; Nada E; Tartaglino B; Marafetti L; Gnavi R Diabetes Obes Metab; 2014 Nov; 16(11):1041-7. PubMed ID: 24702687 [TBL] [Abstract][Full Text] [Related]
17. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211 [TBL] [Abstract][Full Text] [Related]
18. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials. Nauck MA; Meier JJ; Schmidt WE Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752 [No Abstract] [Full Text] [Related]
19. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403 [TBL] [Abstract][Full Text] [Related]
20. Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know. Forsmark CE Pancreatology; 2016; 16(1):10-3. PubMed ID: 26795258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]